Telmisartan and N-acetylcysteine suppress group v secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 367-374

  Sonoki, Kazuo ^a   Iwase, Masanori ^b   Ohdo, Shigehiro ^c   Ieiri, Ichiro ^c   Matsuyama, Naoto ^d   Takata, Yutaka ^a   Kitazono, Takanari ^b  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d R and D Division   (Japan)

Author keywords

human umbilical vein endothelial cells; low density lipoprotein; lysophosphatidylcholine; secretory phospholipase A2; telmisartan; tumor necrosis factor a

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLCYSTEINE; ANGIOTENSIN II; ARYLDIALKYLPHOSPHATASE; GLUCONOLACTONASE; GROUP V SECRETORY PHOSPHOLIPASE A2; GW 3335; HOMOCYSTEIN THIOLACTONASE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; SECRETORY PHOSPHOLIPASE A2; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIATHEROGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ACETYLCYSTEINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; ATHEROSCLEROSIS; BENZIMIDAZOLES; BENZOATES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; GROUP V PHOSPHOLIPASES A2; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867745039     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182646ccc     Document Type: Article

References (22)

1. Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta. 2000;1488:1-19.
2. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem. 2008;77:495-520.
3. Wooton-Kee CR, Boyanovsky BB, Nasser MS, et al. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2004;24:762-767.
4. Hanasaki K, Yamada K, Yamamoto S, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem. 2002;277:29116-29124.
5. Sato H, Kato R, Isogai Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem. 2008;283:33483-33497.
6. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem. 2007;14:3209-3220.
7. Nelken NA, Coughin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88:1121-1127.
8. Sonoki K, Yoshinari M, Iwase M, et al. Glycoxidized low-density lipoprotein enhances MCP-1 mRNA expression in HUVEC. Relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism. 2002;51;1135-1142.
9. Sonoki K, Iwase M, Sasaki N, et al. Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNF alpha-stimulated human endothelial cells. Br J Pharmacol. 2008; 153:1399-1408.
10. Cianchetti S, Del Fiorentino A, Colognato R, et al. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis. 2008;198:22-28.
11. Munoz C, Pascual-Salcedo D, Castellanos MC, et al. Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: Modulation of NF-kB and AP-1 transcription factors activity. Blood. 1996;88:3482-3490.
12. Sonoki K, Iwase M, Sasaki N, et al. Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009; 86:117-123.
13. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension. 2004;43:993-1002.
14. Tian Q, Miyazaki R, Ichiki T, et al. Inhibition of tumor necrosis factoralpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappa B and CCAAT/enhancer-binding protein-beta. Hypertension. 2009;53:798-804.
15. Ries UJ, Mihm G, Narr B, et al. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem. 1993;36: 4040-4051.
16. Luchtefeld M, Bandlow N, Tietge UJ, et al. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. Atherosclerosis. 2007;194:62-70.
17. Rosengren B, Peilot H, Umaerus M, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol. 2006;26:1579-1585.
18. Tischfield JA, Xia YR, Shih DM, et al. Low-molecular-weight, calciumdependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics. 1996;32:328-333.
19. Suckling KE. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs. 2009;18:1425-1430.
20. Murakami M, Sato H, Taketomi Y, et al: Integrated lipidomics in the secreted phospholipase A2 biology. Int J Mol Sci. 2011:12:1474-1495.
21. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-1284.
22. Wootton PT, Arora NL, Drenos F, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet. 2007:16: 1437-1444.